A devoted instructor with the love of phlebotomy is opening up enrollment June 7 in hopes of teaching young students to stick with a purpose.

Medco said its first-quarter earnings before interest, taxes, depreciation and amortisation (EBITDA) was US$332 million, which was superior to the fourth quarter in 2024 "due to proactive cost ...

Complete Medco Energi Internasional stock information by Barron's. View real-time MEDC stock price and news, along with industry-best analysis.

Rusfertide significantly reduced phlebotomy needs in PV patients, with 76.9% achieving clinical response versus 32.9% in the placebo group. The therapy maintained hematocrit levels below 45% in 62 ...

Rusfertide more than doubled the percentage of patients achieving a clinical response, defined as the absence of phlebotomy eligibility during study weeks 20-32 of the trial (76.9% vs 32.9% with ...

“These findings underscore rusfertide’s potential as a first-in-class erythrocytosis-specific treatment for PV and validate more than a decade of scientific innovation originating from Protagonist’s ...

NEWARK, CA, USA & OSAKA, Japan & CAMBRIDGE, MA, USA I June 01, 2025 I Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the ...

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., June 01, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the ...

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control ...